Astellas Pharma’s new non-hormonal menopausal hot flush treatment Veoza can be used in the NHS, NICE says
pharmafile | April 13, 2026 | News story | | Astellas Pharma, menopause
Final draft NICE guidance has recommended Veoza (fezolinetant), made by Astellas Pharma, to treat moderate to severe menopausal hot flushes and night sweats, when hormone replacement therapy (HRT) is not suitable.
Veoza, a non-hormonal treatment, is taken once a day as a 45mg tablet and blocks the nerve pathways in the brain that trigger hot flushes and night sweats.
While HRT remains the first-line treatment option, Veoza addresses a need for those who cannot or do not wish to use it.
Helen Knight, director of medicines evaluation at NICE, said: “For those who are unable to take HRT for varying reasons, options have historically been limited, and we have heard clearly from patients how difficult that can be.
“The evidence shows fezolinetant can meaningfully reduce symptoms, and was found to be cost effective, offering value for the taxpayer. This decision will give much-needed relief to those for whom HRT is unsuitable.”
When HRT is medically not recommended, such as in cases of deep vein thrombosis or pulmonary embolism, Veoza can be used.
It can also be used following a clinical risk assessment in some cases of diabetes or heart disease. Those who do not wish to take HRT are also eligible for this treatment.
Hot flushes and night sweats can disrupt sleep, concentration, relationships and the ability to work, with options for those unable to use HRT, previously, being limited.
Sue Mann, National Clinical Director in Women’s Health for NHS England, said: “Symptoms of menopause including hot flushes and night sweats can affect every part of a women’s life, so this is very welcome news especially for women who are unable to or don’t wish to take hormone replacement therapy.
“It’s another vital treatment option which could help hundreds of thousands of women experiencing menopause to better manage their symptoms and feel more in control of their health.”
Related Content
Five Facts about the menopause
1 Menopause is when periods stop due to decreasing hormone levels. It generally begins between …
Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer
Astellas Pharma, a pharmaceutical company creating medicines to address unmet medical needs, has announced that …
The Pharma Files: With Colin Williams from Astellas Pharma
Pharmafile chats with Colin Williams, Head of Marketing Excellence, Global Capabilities, Learning & Development at …
